Nymox Pharmaceutical (NASDAQ:NYMX) Stock Price Up 6%

Nymox Pharmaceutical Corp (NASDAQ:NYMX) shares rose 6% on Thursday . The company traded as high as $2.19 and last traded at $2.11, approximately 161,025 shares changed hands during mid-day trading. An increase of 243% from the average daily volume of 46,954 shares. The stock had previously closed at $1.99.

Separately, ValuEngine raised shares of Nymox Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

The company has a quick ratio of 5.36, a current ratio of 5.38 and a debt-to-equity ratio of 0.03. The business’s 50-day moving average is $1.77 and its two-hundred day moving average is $1.79.



Nymox Pharmaceutical (NASDAQ:NYMX) last announced its quarterly earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. Nymox Pharmaceutical had a negative net margin of 12,408.26% and a negative return on equity of 189.25%. The company had revenue of $0.02 million during the quarter.

Institutional investors and hedge funds have recently made changes to their positions in the stock. A.R.T. Advisors LLC purchased a new stake in Nymox Pharmaceutical in the second quarter valued at $28,000. Private Advisor Group LLC purchased a new stake in Nymox Pharmaceutical in the second quarter valued at $55,000. Weiss Asset Management LP purchased a new stake in Nymox Pharmaceutical in the second quarter valued at $72,000. Morgan Stanley lifted its position in Nymox Pharmaceutical by 32.5% in the second quarter. Morgan Stanley now owns 110,694 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 27,160 shares during the last quarter. Finally, Wedbush Securities Inc. raised its holdings in shares of Nymox Pharmaceutical by 6.3% in the second quarter. Wedbush Securities Inc. now owns 120,935 shares of the biopharmaceutical company’s stock valued at $175,000 after buying an additional 7,200 shares during the last quarter. 4.03% of the stock is owned by hedge funds and other institutional investors.

Nymox Pharmaceutical Company Profile (NASDAQ:NYMX)

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease.

Featured Article: How does a margin account work?

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.